| Accession | PRJCA011913 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Title | BHV3000-118 | ||||||||
| Relevance | Medical | ||||||||
| Data types | PK concentration | ||||||||
| Organisms | Homo sapiens | ||||||||
| Description | A Phase 1, Randomized, Placebo-controlled, Single- and Multiple- dose, Double-blind Study to Evaluate the Pharmacokinetics and Safety of Rimegepant (BHV-3000) Orally Disintegrating Tablets 75mg in Healthy Adult Chinese Subjects. To evaluate the pharmacokinetics (single and multiple dose daily) profile of rimegepant ODT 75mg in Chinese subjects. To confirm the safety profile of rimegepant ODT 75mg in Chinese subjects, up to 6 doses. | ||||||||
| Sample scope | Multiisolate | ||||||||
| Release date | 2023-01-20 | ||||||||
| Grants |
|
||||||||
| Submitter | Xinghe Wang (wangxh@bjsjth.cn) | ||||||||
| Organization | Beijing Shijitan Hospital, Capital Medical University | ||||||||
| Submission date | 2022-09-16 |
| Resource name | Description |
|---|